
|Articles|November 1, 2003
HAART's Impact on Care
Las Vegas -- The landscape of dermatologic diseases manifested by HIV-positive (HIV+) patients has changed in the era of highly active antiretroviral therapy (HAART), said Clay J. Cockerell, M.D., at the Fall Clinical Dermatology Conference.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5

















